Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.

ABSTRACT:

Purpose

The value of [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG) PET/CT in monitoring prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) is still unclear. The aim of this study was to identify appropriate prognostic dynamic parameters derived from baseline and follow-up [¹⁸F]FDG and dual [¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 PET/CT for monitoring early non-responding mCRPC patients undergoing PSMA-RLT.

Methods

Twenty-three mCRPC patients of a prospective registry (NCT04833517), who were treated with [¹⁷⁷Lu]Lu-PSMA-617 RLT and classified as early non-responders were included in this study. All patients received dual PET/CT imaging with [¹⁸F]FDG and [⁶⁸Ga]Ga-PSMA-11 at baseline and aft

SUBMITTER: Burgard C 

PROVIDER: S-EPMC10827880 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature